Berlin – the YUVEDO Foundation published an economic report by Professor Maier-Rigaud, Paris/Lille, NERA Economic Consulting. According to this report, there is evidence of a market or regulatory failure in the development of causal treatments for Parkinson’s disease and other neurodegenerative disorders (NDEs): high risk in product development is associated with massive costs but relatively little profit potential. This has led many pharmaceutical companies to stop or reduce their research and development investments in drugs or other therapies to prevent and treat NDEs.
Pharmaceuticals play an important role in improving health in modern societies. Yet, for some diseases, the pharmaceutical industry struggles to develop causal or disease-modifying treatments. Some neurodegenerative diseases (NDD) such as Parkinson’s disease (PD), dementia or Alzheimer’s disease (AD) are prominent examples. For example, despite the development of symptomatic treatment for PD more than 50 years ago, no causal or disease-modifying treatment is available.